SPOP promotes ATF2 ubiquitination and degradation to suppress prostate cancer progression

[1]  Yuzhuo Wang,et al.  Intrinsic BET inhibitor resistance in prostate cancer caused by SPOP mutation-mediated BET protein stabilization , 2017, Nature Medicine.

[2]  Andrew H. Beck,et al.  Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4 , 2017, Nature Medicine.

[3]  S. Carr,et al.  Opposing effects of cancer type-specific SPOP mutations on BET protein degradation and sensitivity to BET inhibitors , 2017, Nature Medicine.

[4]  Jinfang Zhang,et al.  Prostate cancer-associated mutation in SPOP impairs its ability to target Cdc20 for poly-ubiquitination and degradation. , 2017, Cancer letters.

[5]  Tongyu Ji,et al.  Long non-coding RNA UCA1 promotes cell progression by acting as a competing endogenous RNA of ATF2 in prostate cancer. , 2017, American journal of translational research.

[6]  A. Jemal,et al.  Cancer statistics, 2017 , 2017, CA: a cancer journal for clinicians.

[7]  L. Qu,et al.  ATF2 predicts poor prognosis and promotes malignant phenotypes in renal cell carcinoma , 2016, Journal of Experimental & Clinical Cancer Research.

[8]  Jihun Lee,et al.  Multiple Weak Linear Motifs Enhance Recruitment and Processivity in SPOP-Mediated Substrate Ubiquitination. , 2016, Journal of molecular biology.

[9]  Yong Zhou,et al.  Activating transcription factor 2 expression mediates cell proliferation and is associated with poor prognosis in human non-small cell lung carcinoma. , 2016, Oncology letters.

[10]  Benjamin G. Bitler,et al.  SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. , 2015, Cell reports.

[11]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[12]  P. Pandolfi,et al.  SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. , 2015, Molecular cell.

[13]  J. Cheville,et al.  Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. , 2015, Molecular cell.

[14]  V. Natarajan,et al.  All-Trans Retinoic Acid Induces TGF-β2 in Intestinal Epithelial Cells via RhoA- and p38α MAPK-Mediated Activation of the Transcription Factor ATF2 , 2015, PloS one.

[15]  K. Rajapakshe,et al.  Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancer. , 2014, Cancer research.

[16]  Yan Tang,et al.  Destruction of DDIT3/CHOP Protein by Wild‐Type SPOP but Not Prostate Cancer‐Associated Mutants , 2014, Human mutation.

[17]  Long Yu,et al.  Destruction of Full-Length Androgen Receptor by Wild-Type SPOP, but Not Prostate-Cancer-Associated Mutants , 2014, Cell reports.

[18]  H. Hieronymus,et al.  SPOP mutations in prostate cancer across demographically diverse patient cohorts. , 2014, Neoplasia.

[19]  E. Schwarz,et al.  TAK1 regulates SOX9 expression in chondrocytes and is essential for postnatal development of the growth plate and articular cartilages , 2013, Journal of Cell Science.

[20]  I. Sumara,et al.  The emerging family of CULLIN3‐RING ubiquitin ligases (CRL3s): cellular functions and disease implications , 2013, The EMBO journal.

[21]  M. Rubin,et al.  Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover , 2013, Proceedings of the National Academy of Sciences.

[22]  Eric Lau,et al.  ATF2 – at the crossroad of nuclear and cytosolic functions , 2012, Journal of Cell Science.

[23]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[24]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[25]  T. Ideker,et al.  PKCε Promotes Oncogenic Functions of ATF2 in the Nucleus while Blocking Its Apoptotic Function at Mitochondria , 2012, Cell.

[26]  H. Hsieh,et al.  NADPH oxidase-mediated redox signal contributes to lipoteichoic acid-induced MMP-9 upregulation in brain astrocytes , 2012, Journal of Neuroinflammation.

[27]  Eric S. Lander,et al.  The genomic complexity of primary human prostate cancer , 2010, Nature.

[28]  L. Chin,et al.  A Role for ATF2 in Regulating MITF and Melanoma Development , 2010, PLoS genetics.

[29]  Z. Ronai,et al.  Emerging roles of ATF2 and the dynamic AP1 network in cancer , 2010, Nature Reviews Cancer.

[30]  J Wade Harper,et al.  Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. , 2009, Molecular cell.

[31]  Stella Logotheti,et al.  The role of ATF‐2 in oncogenesis , 2008, BioEssays : news and reviews in molecular, cellular and developmental biology.

[32]  P. Meltzer,et al.  Suppressor role of activating transcription factor 2 (ATF2) in skin cancer , 2008, Proceedings of the National Academy of Sciences.

[33]  Ximing J. Yang,et al.  Tumor suppressor activity of glucocorticoid receptor in the prostate , 2007, Oncogene.

[34]  Koichi Nagasaki,et al.  Reduced Levels of ATF-2 Predispose Mice to Mammary Tumors , 2006, Molecular and Cellular Biology.

[35]  F. Bethencourt,et al.  The p38 transduction pathway in prostatic neoplasia , 2006, The Journal of pathology.

[36]  Raymond J. Deshaies,et al.  Function and regulation of cullin–RING ubiquitin ligases , 2005, Nature Reviews Molecular Cell Biology.

[37]  R. Halaban,et al.  Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. , 2003, Cancer research.

[38]  J. Yates,et al.  BTB/POZ domain proteins are putative substrate adaptors for cullin 3 ubiquitin ligases. , 2003, Molecular cell.

[39]  B. Dérijard,et al.  Transcription factor ATF2 regulation by the JNK signal transduction pathway , 1995, Science.

[40]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.